Investigational once-weekly triple receptor agonist (GLP-1, GIP, glucagon) studied for weight loss and metabolic control, the leading investigational obesity peptide.
TR8CE uses one simple standard: 0.1 mL of bacteriostatic water per mg. A 5 mg vial takes 0.5 mL of water for a clean 10 mg/mL solution. Larger vials scale the water up to fit the glass.
| Vial size | BAC water | Concentration | 2 mg draws to |
|---|---|---|---|
| 5 mg | 0.5 mL | 10 mg/mL | 20 units |
| 10 mg | 1 mL | 10 mg/mL | 20 units |
| 15 mg | 1.5 mL | 10 mg/mL | 20 units |
| 20 mg | 2 mL | 10 mg/mL | 20 units |
| 30 mg | 3 mL | 10 mg/mL | 20 units |
| 60 mg | 6 mL | 10 mg/mL | 20 units |
Units are shown for a U-100 insulin syringe. A common starting dose is 2 mg. At 10 mg/mL, that draws to 20 units on a U-100 insulin syringe.
Activates the GLP-1, GIP, and glucagon receptors at once. The added glucagon arm raises energy expenditure and thermogenesis on top of appetite suppression and improved insulin sensitivity.
Retatrutide is commonly taken in the morning.
Add 0.5 mL of bacteriostatic water to a 5 mg Retatrutide vial for a 10 mg/mL solution.
A common Retatrutide starting dose is 2 mg, which at 10 mg/mL draws to 20 units on a U-100 insulin syringe.
Draw bacteriostatic water into a syringe, inject it slowly down the inside glass of the Retatrutide vial (not onto the powder), and swirl gently until clear. Store refrigerated and use within the common window.